Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MultiCorp International has engaged Dr Greg Maguire of BioRegenerative Sciences, along with Dr Valentin Isacescu of North County Clinical Research, to work with the company to develop a clear path to begin clinical trials on their patented migraine medicine for eventual approval by the US Food and Drug Administration.
Subscribe to our email newsletter
MultiCorp International CEO Paul D. Lisenby noted that the company is extremely excited to have such a qualified and experienced group to assist the company in mapping out a clear strategy for the migraine medication to gain approval from the FDA.
"While we understand this could be a long process, having a group that is so well versed on the proper procedures clinical trials require to gain approval, we feel we’ve chosen the perfect group to accomplish this portion of the process in the most expeditious manner possible. Once the report is completed in the next four to six weeks, the company will have a clear understanding as to the requirements from the FDA on beginning clinical trials.
"We feel this medication could become a major player in the $3.2 billion dollar segment of the migraine pharmaceutical vertical," Lisenby added.